Zhitong Finance App News, Shiyao Group (01093.HK) announced that the phase II clinical trial of SYH2066 tablets (this product) developed by the Group to treat respiratory syncytial virus (RSV) infection has been officially launched at the first research center in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.